A comparative placebo-controlled clinical trial of the efficacy and safety of interferon β-1a formulations for S.C. administration in patients with remitting multiple sclerosis: First-year results.

Authors
Category Primary study
JournalNeuroscience and Behavioral Physiology
Year 2018
This article has no abstract
Epistemonikos ID: deb09de7efe74acd55eeddd655b0808780f25c0c
First added on: Mar 31, 2022